Introduction

Snakebite is a major public health problem in many African countries including Libya, Tunisia, Algeria and Egypt. It is a particular challenge, although, in some parts of Africa, which is home to more than 400 snake species of which about 30 venomous species, related to four families including: vipersidae, colubridae, atractaspididae, and elapidae and they are recognized to cause human deaths, as reported by the World Health Organization. Cerastes cerastes is one of the snakes frequently related with human mortality in Libya. The Cerastes cerastes venom contains several enzymes showing proteolytic activity and causes multiple kinds of intoxications. The toxicities cause substantial physiopathological changes in liver, skin and heart. Phospholipases A_{2} (PLA_{2}) from Cerastes cerastes for example, has been associated with some toxicity including neurotoxicity, lung toxicity, nephrotoxicity, hepatotoxicity and cardiotoxicity. The lethal cause of snake venom mainly results from its active ingredients such as PLA_{2}. Phospholipid hydrolysas by PLA_{2} releases arachidonic acid whose metabolism results in the formation of potentially toxic reactive oxygen species (ROS) and lipid peroxides. The increase in the activity of liver enzymes indicating the injury of heart, liver and other organs could be accredited to the synergistic action of the venom components.

Anti-snake venom (AVS) is a specific antidote to snake venom actions and the basis of treatment. Monovalent AVS is favoured to the polyvalent kind since it is less perilous to the patient and probably to be more effective in the treatment of the specific bite; though, a species diagnosis ought to be made before the right treatment can be selected. Polyvalent AVS is usually used against snakebite, but it is pricey and contained antibodies from immunized animals; therefore, there are probabilities of adverse reactions due to activation of immune system in many patients.

On the contrary to the impenetrability of accessibility of modern treatment in several countries of developing world where venomous snakes present, many plant species are used as the folk medicine to treat snake bites in Libya mainly as in Tarhouna. Many Libyan plants are suggested for the treatment of snake bite activity. Olea europaea leaves, is one of the plants that has been suggested to be used in conventional herbal medicine against snakebite. Thus, the aim of this study is to screen the anti-snake venom potential of Olea europaea leaves and compared with polyvalent AVS.

Materials and methods

Preparation of aqueous Olea europaea leaf extracts

Leaves of olive trees (Olea europaea) were collected from the Novel lien zone, Tripoli Centre, Tripoli, Libya during July 2018. The leaves (5g) were cleaned and washed with distilled water and dried at a room temperature of 25°C for 20minutes. Dried leaves were grinded in a homogenizer (HO4A Edmund Buhler GmbH, UK) along with 15ml of distilled water. The resulting aqueous solution was filtered using a Millipore filter (0.45µm, GHD Acrodisc GF, UK).

Venoms

Snake (Cerastes cerastes,) venom were extracted by manual stimulation and were obtained in liquid forms, from the Department of Zoology, Faculty of Science, University of Tripoli, Libya and stored at −20°C until use. An aliquot of 7.5μl from the venoms was stored at −20°C until use. An aliquot of 7.5μl from the venoms was used to challenge with LD99 of snake venom in Albino mice.

Experimental animals

Swiss Albino male mice (18±2g) were used for the experiments. In order to reduce the contact caused by environmental alterations...
Olea europaea leaves delay the onset of toxicity of Cerastes cerastes venom in Albino mice

and handling during behavioral studies, mice were acclimatized to the Laboratory Animal Holding Center and laboratory surroundings for three days and at least one hour before to experiments, respectively. Mice were kept under standard conditions with food (low protein diet) and water available ad libitum. The animals were housed six per cage in a light-controlled room (12h light/dark cycle, light on 07:00h) at 27°C and 65% relative humidity. All experiments were performed between 11:30 and 14:00h. Each test group consisted of at least six mice, and each mouse was used only once. All animal experiments were conducted according to guidelines set by Institutional Animal Ethics Committee of University of Tripoli.

Calculation of LD₉₉ of Cerastes cerastes venom

The median lethal dose (LD₉₉) of Cerastes cerastes venom was determined according to the previously developed method. A range of doses of venom in 800μl of physiological saline was injected intraperitoneally using groups of six mice for each venom dose. The LD₉₉ was calculated with the confidence limit at 99% probability by the analysis of mortality occurring within 24h of venom injection. The anti-letal potentials of aqueous Olea europaea leave extracts were determined against LD₉₉ of Cerastes cerastes venom.

Detoxification of venom by extracts

Five groups of mice were used in this study. The first group of six mice received only 100μl (100mg of total protein) of the Cerastes cerastes venom (LD₉₉ 5μg/kg). Groups 2-4 of six mice each (serving as treatment groups) were given an equivalent amount of the Cerastes cerastes venom with 1ml, 1.5ml and 2ml of aqueous Olea europaea leave extracts orally (5g/15ml), respectively. Group 5 of six mice were received 100μl of the Cerastes cerastes venom and ASV. The number of mortality was recorded within 24h.

Statistical analysis

The difference among various treated groups and control group were analysed using one-way-ANOVA followed using unpaired Student’s test. The results were expressed as the mean ± SEM of the number of experiments done, with P<0.05 indicating significant difference between groups.

Results and discussion

Calculation LD₉₉ of Cerastes cerastes venom

Lethality data of Cerastes cerastes venom was calculated. The LD₉₉ of Cerastes cerastes venom from this study was 5μg/kg.

Acute toxicity of Cerastes cerastes venom and its neutralization by aqueous Olea europaea leave extracts and antivenom

The Cerastes cerastes venom at the dose 5μg/kg (LD₉₉) produces 100% mortality in mice. The aqueous Olea europaea leave extracts significantly increases mean survival time up to 4±0.6hours and the protection fold could not protect animals from death when Cerastes cerastes venom used alone. The aqueous Olea europaea leave extracts when used at the dose of 2ml (5g/15ml) was found to be more effective against Cerastes cerastes venom (4hours) when compared with 3.4hours shown by aqueous Olea europaea leave extract scavenging the number of experiments done, with P<0.05 indicating significant difference between groups. The toxins of Cerastes cerastes venom are composed of neurotoxin, cardiotoxin, enzymes and proteins. The victim might die from respiratory paralysis which is the major cause of death. ASV and assisted ventilation can save life in many cases. Nevertheless, polyvalent antivenom carries a risk of severe adverse reactions and other problems such as difficulty to manage and usage, variety of dosage and high cost. Furthermore, antivenom occasionally does not offer sufficient protection against snake envenomation, particularly local poisoning. The use of plants against the effect of snakebite has long been documented, even in modern times.

In Libya, several plants are recognized against snake envenomation particularly in the North South region of Libya (mainly Tarhouna). It was observed that aqueous Olea europaea leave extract when given to the mice after they received snake venom of Cerastes cerastes venom significantly increased mean survival time and the results were found better when it was used at higher dose (2ml of 5g/15ml). This could be possible due to inactivation or precipitation of active venom components by the aqueous Olea europaea leave extract which is consistent with the result obtained with similar studies.

The delayed survive also could be related to the interactions of AOLE components (which were mainly polyphenolic components) with snake venom which is in consistency with previous studies reporting that polyphenolic secondary metabolites are able to inhibit PLA₉. For example, quercetin, kaempferol, galangin, naringenin, artemetin and other flavonoids can inhibit toxins from snake venom. They found that flavonoids usually exert their inhibitory effect through hydrophobic interactions with A and B rings and aromatic or hydrophobic amino acid residues in the protein. In addition, another research group found that Ar-turmerone which is a phenolic compound isolated from the Curcuma longa (Zingiberaeaceae) plant has a strong inhibitory effect against hemorrhage and lethality caused by B. jararaca and Cd. terrificus snake venom. The effect was attributed to the interaction with PLA₉. It has also been reported that 4-nerolidylecetol (a hydroxylated phenolic compound) an extract from Piper umbellatum and P. peltatum (Piperaceae) is able to inhibit the myotoxic activities of PLA₉ and is able to interact and inhibit the function of PLA₉, Araya and Lomonte, found that caffeic acid which is one of the components of AOLE, can interact with proteins via hydrogen bonds, inhibiting enzyme function and acting as antioxidant. They found that strong interactions may cause conformational changes in the protein structure. The interaction of caffeic acid with snake venom were confirmed by Shimabuku and collaborators, who crystallized PrTX-I (basic Lys49-PLA₉ from B. pirajai snake venom) in the presence of the inhibitor caffeic acid. The electron-density map clearly signifies the presence of three caffeic acid molecules interacting with the C-termius of the protein. It is also reported that patients with snake bite envenomation had increased oxidants (myeloperoxidase and Linoelic acid hydroperoxides) and decreased antioxidants (Human serum paraoxonase, ARLY, and-SH) and these results demonstrate that snake bites are associated with a shift to oxidative status but therapy with antioxidants can lead to an increase in the antioxidant defense system and thus improvements in clinical symptoms.

Conclusion

Antivenom is the ultimate treatment for venomous snakebites and must be administered as soon as possible after a bite. First aid measures should be directed at reducing systemic toxicity by limiting lymphatic flow. Rest, splints, and evasion of movement should decrease movement of the involved extremity. Positioning of the extremity below or at the level of the heart should be individualized.
for snakebites with severe and potentially fatal systemic toxicity, systemic toxicity may be hindrance by positioning the extremity below the heart, while for snakebites with severe local tissue damage and less systemic toxicity, positioning the extremity below the heart could increase local toxicity. Thus, it can be concluded from the study that aqueous Olea europaea leaf extract might have antivenom activity against Cerastes cerastes venom. Results are comparable with the antivenom. Further elaborative work is necessary for the better understanding of the mechanism of venom inhibition. Detailed clinical studies in this direction are necessary to confirm this claim in human beings.

Acknowledgments

None.

Conflicts of interest

Authors declare there is no conflict of interest.

References

1. Appiah B. Snakebite neglect rampant in Africa. CMAJ. 2012;184(1):27–28.
2. Harrison RA, Oluoch GO, Ainsworth S, et al. Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. PLoS Negl Trop Dis. 2017;11(10).
3. Mohamed AH, Ibrahim FK, Fattah MM, et al. Toxic fractions of Cerastes cerastes venom. Jpn J Med Sci Biol. 1977;30(4):205–207.
4. Siddiqi AR, Shafqat J, Zaidi ZH, et al. Characterization of phospholipase A2 from the venom of Horned viper (Cerastes cerastes). FEBS Lett. 1991;278(1):14–16.
5. Gasanov SE, Gasanov NE, Rael ED. Phospholipase A2 and cobra venom cytotoxin Vc5 interactions and membrane structure. Gen Physiol Biophys. 1995;14(2):107–123.
6. Alzahaby M, Rowan EG, Young LC, et al. Some pharmacological studies on the effects of Cerastes vipera (Sahara sand viper) snake venom. Toxicol. 1995;33(10):1299–1311.
7. Cavalcante WLG, Noronha Matos JB, Timoteo MA, et al. Neuromuscular paralysis by the basic phospholipase A2 subunit of crototoxin from Crotalus durissus terrificus snake venom needs its acid chaperone to concurrently inhibit acetylcholine release and produce muscle blockade. Toxicol Appl Pharmacol. 2017;334:8–17.
8. Hamza M, Idris MA, Maiyaki MB, et al. Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa. PLoS Negl Trop Dis. 2016;10(3):568.
9. Ahmed SM, Ahmed M, Nadeem A, et al. Emergency treatment of a snake bite: Pearls from literature. J Emerg Trauma Shock. 2008;1(2):97–105.
10. Brahmane RI, Pathak SS, Wannali VV, et al. Partial in vitro and in vivo red scorpion venom neutralization activity of Andrographis paniculata. Pharmacognosy Res. 2011;3(1):44–48.
11. Cherifi F, Saoud S, Laraba Djebari F. Molecular modeling, biochemical characterization, and pharmacological properties of Ce3 -SPase: A platelet-aggregating thrombin-like enzyme purified from Cerastes cerastes venom. J Biochem Mol Toxicol. 2018;165.
12. Segura A, Herrera M, Vargas M, et al. Preclinical efficacy against toxic activities of medically relevant Bothrops sp. (Serpentes: Viperidae) snake venoms by a polyspecific antivenom produced in Mexico. Rev Biol Trop. 2017;65(1):345–350.
13. WHO/SEARO Guidelines for the clinical management of snake bites in the Southeast Asian region. Southeast Asian J Trop Med Public Health. 1999;30(1):1–85.
14. Panda S, Kumari L. Anti-Ophidian Properties Of Herbal Medicinal Plants: Could It Be A Remedy For Snake Bite Envenomation?. Curr Drug Discov Technol. 2018.
15. Upasani MS, Upasani SV, Beldar VG, et al. Infrequent use of medicinal plants from India in snakebite treatment. Integr Med Res. 2018;7(1):9–26.
16. Cotrim CA, Oliveira SC, Diz Filho EB, et al. Quercetin as an inhibitor of snake venom secretory phospholipase A2. Chem Biol Interact. 2011;189(1–2):9–16.
17. Tiel TK, Hage LI, Cambraia RS, et al. Rosmarinic acid, a new snake venom phospholipase A2 inhibitor from Cordia verbenacea (Boraginaceae): antisera action potentiation and molecular interaction. Toxicol. 2005;46(3):318–327.
18. Soares AM, Tiel TK, Marcussi S, et al. Medicinal plants with inhibitory properties against snake venoms. Curr Med Chem. 2005;12(22):2625–2641.
19. Lattig J, Bohl M, Fischer P, et al. Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design. J Comput Aided Mol Des. 2007;21(8):473–483.
20. Ferreira LA, Henriques OB, Andronio AA, et al. Antivenom and biological effects of ar-turmerone isolated from Curcuma longa (Zingiberaceae). Toxicol. 1992;30(10):1211–1218.
21. Nunez V, Castro V, Murillo R, et al. Inhibitory effects of Piper umbellatum and Piper peltatum extracts towards myotoxic phospholipases A2 from Bothrops snake venoms: isolation of 4-nerolidylcatechol as active principle. Phytochemistry. 2005;66(9):1017–1025.
22. Araya C, Lomonte B. Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms. Cell Biol Int. 2007;31(3):263–268.
23. Lomonte B, Angulo Y, Moreno E. Synthetic peptides derived from the C-terminal region of Lys49 phospholipase A2 homologues of snake venoms. Cell Biol Int. 2007;31(3):263–268.
24. Shimabuku PS, Fernandes CA, Magro AJ, et al. Crystallization and preliminary X-ray diffraction analysis of a Lys49-phospholipase A2 complexed with caffeic acid, a molecule with inhibitory properties against snake venoms. Acta Crystallography Sect F Struct Biol Cryst Commun. 2011;67(2):249–252.
25. Zengin S, Al B, Yarbil P, et al. Oxidant/antioxidant status in cases of snake bite. J Emerg Med. 2013;45(1):39–45.